Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Madaras Kelly, Karl ^a   Jones, Makoto ^b   Remington, Richard ^c   Caplinger, Christina ^d   Huttner, Benedikt ^e   Samore, Matthew ^f  

^a IDAHO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c Quantified Inc   (United States)

^d Boise Veterans Affairs Medical Center   (United States)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial de escalation; Antimicrobial spectrum; Broad spectrum antimicrobials; Healthcare associated pneumonia; Humans; Multi drug resistance; Spectrum score

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERTAPENEM; GEMIFLOXACIN; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL DEESCALATION; ANTIMICROBIAL THERAPY; ARTICLE; DELPHI STUDY; ELECTRONIC MEDICAL RECORD; HEALTH CARE ASSOCIATED PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LIKERT SCALE; ORAL DRUG ADMINISTRATION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPECTRUM SCORE; CLINICAL PRACTICE; ELECTRONIC HEALTH RECORD; GOVERNMENT; HOSPITALIZATION; HUMAN; MICROBIAL SENSITIVITY TEST; PNEUMONIA; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; UNITED STATES; VALIDATION STUDY;

ANTI-INFECTIVE AGENTS; ELECTRONIC HEALTH RECORDS; HOSPITALIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; PRACTICE PATTERNS, PHYSICIANS'; SENSITIVITY AND SPECIFICITY; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84929307512     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0933-9     Document Type: Article

References (53)

1. Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-77.
2. Anon. Centers for Disease Control. Evidence to Support Stewardship. Available at: http://www.cdc.gov/getsmart/healthcare/evidence.html . Last accessed August, 8, 2014.
3. Fishman N, Patterson J, Saiman L, Srinivasan A, Trivedi KK, van Schooneveld T, et al. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society. Infect Control Hosp Epidemiol. 2012;33(4):322-7.
4. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis. 2007;45 Suppl 3:S177-83.
5. Masterton RG. Antibiotic de-escalation. Crit Care Clin. 2011;27(1):149-62.
6. Kollef MH. Providing appropriate antimicrobial therapy in the intensive care unit: surveillance vs. de-escalation. Crit Care Med. 2006;34(3):903-5.
7. Madaras-Kelly KJ, Jones M, Remington R, Hill N, Huttner B, Samore M. Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach. Infect Control Hosp Epidemiol. 2014;35(9):1103-13.
8. Anon. American Thoracic Society; Infectious Diseases Society of America. Management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
9. Anon. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 2012: M100-S22; M076-A9
10. Anon. Clinical Laboratory Standards Institute. Methods for dilution of antimicrobial susceptibility tests for bacteria that group aerobically; 2012. p. M07-A9.
11. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford guide to antimicrobial therapy 2012 (42nd Edition). Sperryville: Antimicrobial Therapy, Inc; 2012.
12. Anon. Food and Drug Administration. Daily Med. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm . Last accessed: August 8, 2014
13. Anadiotis L, Maskell JP, Sefton AM. Comparative in-vitro activity of penicillin alone and combined with gentamicin against clinical isolates of Streptococcus pneumoniae with decreased susceptibility to penicillin. Int J Antimicrob Agents. 2002;19(3):173-81.
14. Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008;145(6):951-8.
15. Biedenbach DJ, Jones RN. In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods. Diagn Microbiol Infect Dis. 2001;39(1):49-53.
16. Blondeau JM, Yaschuk Y, Suter M, Vaughan D. In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group. J Antimicrob Chemother. 1999;43 Suppl A:3-23.
17. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis. 2005;52(3):173-9.
18. Citron DM, Goldstein EJ, Kenner MA, Burnham LB, Inderlied CB. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children. Clin Infect Dis. 1995;20 Suppl 2:S356-60.
19. De Fátima Silva Lopes M, Ribeiro T, Abrantes M, Figueiredo Marques JJ, Tenreiro R, Crespo MT. Antimicrobial resistance profiles of dairy and clinical isolates and type strains of enterococci. Int J Food Microbiol. 2005;103((2):191-8.
20. Edelstein PH, Meyer RD. Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob Agents Chemother. 1980;18(3):403-8.
21. Finland M, Garner C, Wilcox C, Sabath LD. Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics. J Infect Dis. 1976;134(SUPPL):S297-307.
22. Flamm RK, Sader HS, Jones RN. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. Diagn Microbiol Infect Dis. 2014;78(4):437-42.
23. Forward KR, Low DE, Laverdiere M, Rennie R, Simor AE, Franks PA. Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. Can J Infect Dis. 1997;8(3):147-53.
24. Fuchs PC, Barry AL, Thornsberry C, Jones RN. In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. Antimicrob Agents Chemother. 1984;25(3):392-4.
25. Hamamoto K, Shimizu T, Fujimoto N, Zhang Y, Arai S. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2001;45(6):1908-10.
26. Havlichek D, Saravolatz L, Pohlod D. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrob Agents Chemother. 1987;31(10):1529-34.
27. Ikejima H, Yamamoto H, Ishida K, Terakubo S, Kaku M, Shimada J. Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae. J Infect Chemother. 2001;7(2):121-3.
28. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 1998;31(3):437-51.
29. Karlowsky JA, Adam HJ, Decorby MR, Lagacé-wiens PR, Hoban DJ, Zhanel GG. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob Agents Chemother. 2011;55(6):2837-46.
30. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother. 2001;45(9):2604-8.
31. Kenny GE, Cartwright FD. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin. Antimicrob Agents Chemother. 1991;35(3):587-9.
32. Koeth LM, Good CE, Appelbaum PC, Goldstein EJ, Rodloff AC, Claros M, et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother. 2004;53(6):1039-44.
33. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baguero F, Loza E, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother. 2001;45(6):1860-7.
34. Pasculle AW, Dowling JN, Weyant RS, Sniffen JM, Cordes LG, Gorman GM, et al. Susceptibility of Pittsburgh pneumonia agent (Legionella micdadei) and other newly recognized members of the genus Legionella to nineteen antimicrobial agents. Antimicrob Agents Chemother. 1981;20(6):793-9.
35. Quentin C, Cantet P, Renaudin H, Bebear C. Antibiotic sensitivity of Mycoplasma pathogenic for man. Pathol Biol. 1985;33(3):205-12.
36. Rosenblatt JE, Stewart PR. Lack of activity of sulfamethoxazole and trimethoprim against anaerobic bacteria. Antimicrob Agents Chemother. 1974;6(1):93-7.
37. Sader HS, Farrell DJ, Flamm RK, Jones RN. Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother. 2014;58(4):2274-80.
38. Schülin T, Wennersten CB, Ferraro MJ, Moellering RC, Eliopoulos GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother. 1998;42(6):1520-3.
39. Stout JE, Sens K, Mietzner S, Obman A, Yu VL. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents. 2005;25(4):302-7.
40. Tunér K, Nord CE. Antibiotic susceptibility of anaerobic bacteria in Europe. Clin Infect Dis. 1993;16 Suppl 4:S387-9.
41. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother. 2004;53 Suppl 2:ii11-21.
42. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, et al. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother. 2013;68 Suppl 1:i7-22.
43. Schneider R, Bagby J, Carlson R. Bar-code medication administration: a systems perspective. Am J Health Syst Pharm. 2008;65(23):2216. 8-9.
44. Aronsky D, Haug PJ, Lagor C, Dean NC. Accuracy of administrative data for identifying patients with pneumonia. Am J Med Qual. 2005;20(6):319-28.
45. Jones M, DuVall SL, Spuhl J, Samore MH, Nielson C, Rubin M. Identification of methicillin-resistant Staphylococcus aureus within the nation's veterans affairs medical centers using natural language processing. BMC Med Inform Decis Mak. 2012;12:34.
46. Anon. Centers for Disease Control. Core Elements of Hospital Antibiotic Stewardship Programs. Available at: http://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html . Last accessed August 8, 2014.
47. Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006;333(7580):1193. Epub 2006 Nov 7.
48. Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg. 1996;223(3):303-15.
49. Nussenblatt V, Avdic E, Cosgrove S. What is the role of antimicrobial stewardship in improving outcomes of patients with CAP? Infect Dis Clin North Am. 2013;27(1):211-28.
50. Silva BN, Andriolo RB, Atallah AN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. 2013;3:CD007934.
51. Kollef MH, Morrow LE, Niederman MS, Leeper KV, Anzueto A, Benz-Scott L, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129(5):1210-8.
52. Van den Bosch CM, Hulscher ME, Natsch S, Gyssens IC, Prins JM, Geerlings SE, et al. Development of quality indicators for antimicrobial treatment in adults with sepsis. BMC Infect Dis. 2014;14:345.
53. Buyle FM, Metz-Gercek S, Mechtler R, Kern WV, Robays H, Vogelaers D, et al. Prospective multicentre feasibility study of a quality of care indicator for intravenous to oral switch therapy with highly bioavailable antibiotics. J Antimicrob Chemother. 2012;67((8):2043-6.